Athersys, Inc. Receives Orphan Drug D...

Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

There are 2 comments on the BioSpace story from Jul 10, 2012, titled Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome. In it, BioSpace reports that:

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)

Join the discussion below, or Read more at BioSpace.


Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Lower Availability of Omega-3 fatty Acids Assoc... Nov 27 Nataly 1
News $160B deal to combine Pfizer and Allergan raise... Nov 26 Mite Be 21
News CDC: 'Alarming' increase in STDs Nov 25 Belles Echoes 123
News Pfizer to buy Allergan in $160 billion deal Nov 25 Cordwainer Trout 6
News Press release distribution, EDGAR filing, XBRL,... Nov 23 Buckle Up 1
News Two murdered at Texas campsite are from Oceanside Nov 19 James McMillan 1
News US survey shows higher rate of autism in children Nov 13 Vaccines Autism S... 1
More from around the web